Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 19, 2003, Pages 3277-3280

  Axford, Lorraine ^a,c   Boot, John R ^a   Hotten, Terrence M ^a   Keenan, Martine ^a   Martin, Fionna M ^a   Milutinovic, Sandra ^a   Moore, Nick A ^a   O'Neill, Michael F ^a   Pullar, Ian A ^a   Tupper, David E ^a   Van Belle, Kristel R ^b   Vivien, Vincent ^a,d  

^a ELI LILLY AND COMPANY   (United States)

^b Eli Lilly Benelux   (Belgium)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d Bioreason   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE UPTAKE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORBORNANE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DEPRESSION; DIELS ALDER REACTION; DRUG SYNTHESIS; HYDROGENATION; STRUCTURE ACTIVITY RELATION;

BETULACEAE;

EID: 10744233215     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00660-7     Document Type: Article

References (29)

1. Hindmarch I. Hum. Psychopharmacol. Clin. Exp. 16:2001;203.
2. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. J. Pharmacol. Exp. Ther. 283:1997;1305.
3. Baldessarini, R. J. Drugs and the Treatment of Psychiatic Disorders. In The Pharmacological Basis of Therapeutics, 7th ed.; Goodman, A. G., Gilman L. S., Rall, T. W., Murad, F., Eds.; Macmillan: New York, 1985, p 416.
4. Nelson J.C. J. Clin. Psychiatry. 59:1998;65.
5. Masand P.S., Anand V.S., Tanquary J.F. Depression Anxiety. 7:1998;89.
6. Bodkin J.A., Kasser R.A., Wines J.D., Gardner D.M., Baldessarini R.J. J. Clin. Psychiatry. 58:1997;137.
7. Dewan M.J., Anand V.S. J. Nervous Mental Dis. 187:1999;96.
8. Ashton A.K., Rosen R.C. J. Clin. Psychiatry. 59:1998;112.
9. Wedney S., Howard J.L., Large B.T., Pullar I.A. Biochem. Pharm. 27:1978;2907.
10. i (nM): 5HT <5, DA<20 and NE<50. Catalyst™, version 4.5 (Accelerys, San Diego, CA, USA). Common feature approach generated within Catalyst, using BEST with an energy limit at 10 Kcal/mol, default dictionary definition, feature spacing set to 150 picometer with variable weight and tolerance.
11. (a) Davies H.M.L., Kuhn L.A., Thornley C., Matasi J.J., Sexton T., Childers S.R. J. Med. Chem. 44:2001;1509.
12. (b) Davies H.M.L., Gilliat V., Kuhn L.A., Saikali E., Ren P., Hammand P.S., Sexton T., Childers S.R. J. Med. Chem. 39:1996;2554.
13. (c) Javanmard S., Deutsch H.M., Collard M.M., Kuhar M.J., Schweri M.M. J. Med. Chem. 42:1999;4836.
14. Kobagashi S., Hachiya I., Araki M., Isuitani H. Tetrahedron Lett. 34:1993;4535.
15. 1H (ppm) δ 6.05 (d, 2H), 6.50 (d, 2H), ratio 79:21. The major isomer was confirmed as endo by nOe: interactions are observed between the bridgehead proton and the aromatic ring; such an interaction is not observed for the exo isomer.
16. r (E2) 22.2 min. Analytical column size: 250×4.6 mm 1D and for preparative work: 250×20 mm 1D.
17. (a) Evans D.A., Murry J.A., von Matt P., Norcross R.D., Miller S.J. Angew. Chem., Int. Ed. Engl. 34:1995;798.
18. (b) Evans D.A., Miller S.J., Lectka T. J. Am. Chem. Soc. 115:1993;6460.
19. r (E2) 40.89 min. Absolute stereochemistry not assigned. Absolute stereochemistry was assigned later by X-ray crystallographic analysis of Ar=naphthyl, 16 d.
20. Evans D.A., Chapman K.T., Bisaha J. J. Am. Chem. Soc. 110:1988;1238.
21. Evans D.A., Chapman K.T., Bisaha J. J. Am. Chem. Soc. 106:1984;4261.
22. r (E2) 15.21 min.
23. 2NH) HPLC/MS profiling.
24. (a) Grahame-Smith D.G. J. Neurochem. 18:1971;856.
25. (b) Grahame-Smith D.G. J. Neurochem. 18:1971;1053.
26. (c) Bogeso K.P., Christensen A.V., Hyttel J., Liljeforss T. J. Med. Chem. 28:1985;1817.
27. Agoston G.E., Wu J.H., Izenwasser S., George C., Kline R.H., Hauck Newman A. J. Med. Chem. 40:1997;4329.
28. (a) Peuch A.J., Chermant R., Poncelet M., Doare L., Simon P. Psychopharmacology. 75:1981;84.
29. (b) Redrobe J.P., Bourin M., Colombel M.C., Baker G.B. Psychopharmacologia. 138:1998;1.